Market Intelligence, Preclinical Progress, and High-Purity Reagents for Apoptosis-Targeted and E3 Ligase Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BFAR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BFAR Full-Length & RING Domain Recombinant Protein (wild-type and mutant). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View BFAR Products |
| Gene Delivery | BFAR Promise-ORF / Lentivirus. Full-length ORF for stable cell lines preserving ER/mitochondrial membrane conformation. | View BFAR Products |
| Benchmark Ab | Anti-BFAR (Research Grade). Recombinant monoclonal for SPR, Western blot, and cellular validation. | View BFAR Products |
| Validator | BFAR siRNA Set. For knockdown verification and rescue assay specificity control. | View BFAR Products |
| Related Target BCL2 | BCL2. Core apoptosis pathway node; synergistic target for combination studies. | View BCL2 Products |
| Related Target TNFRSF1A | TNFRSF1A (TNFR1). Direct BFAR interactor; essential for TNF-axis mechanism validation. | View TNFRSF1A Products |
| Related Target BAX | BAX. Downstream apoptosis effector suppressed by BFAR. | View BAX Products |
| Related Target FAS | FAS (CD95). Death receptor pathway modulated by BFAR interactions. | View FAS Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RING domain enzymatic & E3 ligase activity profiling | Full-length and truncated RING domain proteins (>95% purity, sequence verified) for in vitro ubiquitination and binding assays. |
| Multi-pass membrane expression & stable cell line generation | Premade BFAR Lentivirus particles for rapid, high-fidelity expression preserving native membrane topology. |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available, HEK293 Expressed, Endotoxin <1 EU/µg. |
| Target specificity & knockdown false-positive control | Sequence-verified BFAR siRNA included for knockdown rescue and off-target exclusion; benchmark antibodies provided. |
Live BFAR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The Bifunctional Apoptosis Regulator (BFAR) is an emerging therapeutic target in preclinical oncology. BFAR suppresses both intrinsic (BAX-mediated) and extrinsic (FAS-mediated) apoptosis, acting as a critical survival node in tumors. Importantly, BFAR possesses an intrinsic RING finger domain with E3 ubiquitin ligase activity, making it an attractive novel handle for PROTAC (Proteolysis Targeting Chimera) drug design, bypassing resistance to CRBN/VHL-based degraders. The therapeutic landscape remains in early-stage discovery, with first-in-class programs expected in hematologic malignancies and solid tumors driven by apoptotic dysregulation. Notable mutant variants include dbSNP:rs11546303 and rs35377618, which may influence protein stability and drug response. Combination regimens alongside BCL-2 pathway inhibitors represent a critical future trend.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic / Early Biotech | Solid Tumors (Apoptosis Evasion) | Ligand binding and ubiquitination assays (Need high-purity RING/SAM domain proteins) |
| PROTAC / Degrader | Targeted Degradation Pipelines | Refractory Cancers | Ternary complex SPR/BLI, ubiquitination assays (Need precisely truncated active-conformation E3 domains) |
| Peptide / Macrocycle (PPI Disruptor) | Structural Biology Consortia | TNF-Driven Cancers | Heterodimer binding kinetics (Need full-length & BAR domain proteins) |
| RNAi / ASO | Preclinical Discovery | Neuroblastoma, Lung Cancer | Cell-based knockdown assays (Need reliable siRNA and benchmark Abs) |